Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
We found ~20% eradication of cCIS from TURBT alone. cCIS was a poor metric of MRD, performing worse than abnormal pretreatment urinary cytology and utDNA. These urine biomarkers are more objective MRD measures than cCIS for NMIBC risk stratification and treatment assessment.
Authors
- Judy Sarungbam (ORCID: https://orcid.org/0000-0002-7443-8123)
- Timothy F. Donahue (ORCID: https://orcid.org/0000-0003-1855-1794)
- Eugene J. Pietzak (ORCID: https://orcid.org/0000-0002-5121-5701)
- Irina Ostrovnaya (ORCID: https://orcid.org/0000-0003-1783-0070)
- Gamze Gokturk Ozcan (ORCID: https://orcid.org/0000-0003-4758-2020)
- Melissa McCarter
- NEETA D'Souza
- Gopa Iyer
- A Goh
- Anthony Martinez Benitez
- Morgan Tomberlin
- C. Roger White (ORCID: https://orcid.org/0000-0002-9589-0610)
- Andrew Katims
- Sadra Sepehri
- Merve Basar
- S. Jia
- Pan Du
- Syed Muneeb Alam
- Max Kates
- Manuel De Jesus Escano
- Bernard H Bochner
- David B Solit
- Oscar Lin
- Mark Farha
- Hikmat Al-Ahmadie
Institutions
- Westchester Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- SUNY Downstate Health Sciences University (US)
- Cornell University (US)
- Yale University (US)
- Doctors Hospital at Renaissance (US)
- Biopredic (France) (FR)
- Johns Hopkins Hospital (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3395
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00